AstraZeneca正在投资4.45亿美元,以扩大其得克萨斯州工厂,将全球药物Lokelma的产量翻一番。 AstraZeneca is investing $445 million to expand its Texas plant, doubling production of the global drug Lokelma.

AstraZeneca正在扩大其在得克萨斯州Coppell的设施,投资4.45亿美元,使Lokelma的产量翻一番,Lokelma是一种高钾含量的药物,增加了9 000平方英尺、两条新制造线以及升级的实验室和仓库。 AstraZeneca is expanding its Coppell, Texas, facility with a $445 million investment to double production of Lokelma, a drug for high potassium levels, adding 9,000 square feet, two new manufacturing lines, and upgraded labs and warehousing. 该网站是Lokelma唯一的全球生产商,供应50多个国家。 The site is the sole global producer of Lokelma, supplying over 50 countries. 这项扩张支持AstraZeneca五年内500亿美元的美国投资计划, The expansion supports AstraZeneca’s $50 billion U.S. investment plan over five years, which also includes a major Virginia facility. 得克萨斯站点雇用了250多人,旨在改善全球获得药品的机会。 The Texas site employs over 250 people and aims to improve global access to the medication.